Skip to main content

Table 3 Comparison between liver function results in the studied patients

From: Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs)

N = 200 At the start of treatment After 1 month of treatment At the end of treatment P-value
ALT Mean 60.5 51.3 37.2 P1 = < 0.001 HS
P2 = < 0.001 HS
P3 = < 0.001 HS
± SD 12.3 11.8 7.9
AST Mean 55.6 42.3 35.7 P1 = < 0.001 HS
P2 = < 0.001 HS
P3 = < 0.001 HS
± SD 13.2 12.7 10.2
ALP Mean 285.3 120.6 90.2 P1 = < 0.001 HS
P2 = < 0.001 HS
P3 = < 0.001 HS
± SD 36.4 24.3 19.5
GGT Mean 60.7 55.2 25.8 P1 = < 0.001 HS
P2 = < 0.001 HS
P3 = < 0.001 HS
± SD 17.8 15.5 13.2
Total bilirubin Mean 2.3 1.5 1.01 P1 = < 0.001 HS
P2 = < 0.001 HS
P3 = < 0.001 HS
±SD 0.9 0.8 0.5
Direct bilirubin Mean 0.9 0.5 0.1 P1 = < 0.001 HS
P2 = < 0.001 HS
P3 = < 0.001 HS
± SD 0.3 0.1 0.02
Albumin Mean 2.2 2.3 2.4 P1 = 0.151 NS
P2 = 0.06 NS
P3 = 264 NS
± SD 0.9 0.4 1.2
INR Mean 1.2 1.09 1.1 P1 = < 0.001 HS
P2 = < 0.001 HS
P3 = < 0.001 HS
± SD 0.2 0.3 0.2
  1. X2: Chi-square test
  2. S: p-value < 0.05 is considered significant
  3. HS: p-value < 0.001 is considered highly significant
  4. P1: refers to the statistical difference between the start of DAA and 1 month after DAA
  5. P2: refers to the statistical difference between the start of DAA and the end of DAA
  6. P3: refers to the statistical difference between 1 month after DAA and the end of DAA